- Clene presented clinical data at the 2024 American Academy of Neurology (“AAN”) Annual Meeting, demonstrating that long-term CNM-Au8® treatment resulted in significant evidence of repair and remyelination across multiple paraclinical endpoints
- Clene entered into a sub-award grant agreement with Columbia University under the previously announced National Institute of Health (“NIH”) Grant
- Clene announced the publication of “Protein Corona Composition of Gold Nanocatalysts” in the ACS Pharmacology & Translational Science journal
Clene (NASDAQ: CLNN), a late-stage clinical biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), along with its wholly-owned subsidiary Clene Nanomedicine, Inc., recently announced its first quarter 2024 financial results and provided an important update on the CNM-Au8 clinical program for MS (https://ibn.fm/hfocz).
In April, Clene presented clinical data at the 2024 AAN Annual Meeting, demonstrating that long-term CNM-Au8 treatment resulted in significant evidence of repair and remyelination across multiple paraclinical endpoints. Those participants initially randomized to CNM-Au8 treatment showed…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]